上海心瑋醫療科技股份有限公司 - B - H股 06609Prospectus Information

Prospectus Information
IPO Timeline
Broker Results (T-2)
2021-08-18
Some brokers release in afternoon
Grey Market (T-1)
2021-08-19
Afternoon
HKEX Allotment (T-1)
2021-08-19
Evening
Registrar Allotment (T-1)
2021-08-19
Evening
Listing Day (T)
2021-08-20
First day of trading
Company Overview
Stock Name上海心瑋醫療科技股份有限公司 - B - H股
Stock Code06609
Company Full Name上海心瑋醫療科技股份有限公司 - B - H股
Industry醫療保健
Principal Activities主要於中國從事研發、制造及銷售神經介入及心臟醫療器械。
Listing Date2021-08-20
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市張江高科技產業東區瑞慶路590號9幢南2層
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttp://www.heartcare.com.cn
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo data
Offering Information
Offering Mechanism To be extracted
Offer PriceHK$ 171.00 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering SharesTo be extracted
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)To be confirmed
Stabilizing Manager (Greenshoe)
Cornerstone Share45.5%
Clawback TiersTo be extracted
Reallocation OptionTo be confirmed
Total Global Offering SizeHK$ 564,471,000
Valuation & Financials
Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)To be extracted
P/E RatioTo be extracted
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day Performance
First Day CloseHK$ 129.0
First Day OpenHK$ 141.2
First Day Change-24.56%
First Day Volume2053800.0
First Day Turnover281742000.0
Use of Proceeds
Use of Proceeds1、約45.3%或約459.7百萬港元預期將分配至我們的核心產品; 2、約39.9%所或約404.9百萬港元預期將分配至我們管線內的其他在研產品; 3、約4.8%或約48.7百萬港元用于為透過內部研究提升研發能力及持續擴充產品組合提供資金; 4、約10.0%或約101.5百萬港元預期將用作營運資金及一般企業用途。
Underwriting Syndicate
Joint Sponsors (2)
高盛(亚洲)有限责任公司 CE ACC536 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (2)
高盛(亚洲)有限责任公司 CE ACC536 中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (3)
高盛(亚洲)有限责任公司 CE ACC536 中国国际金融香港证券有限公司 CE AEN894 富途证券国际(香港)有限公司 CE AZT137
Joint Lead Managers (3)
高盛(亚洲)有限责任公司 CE ACC536 中国国际金融香港证券有限公司 CE AEN894 富途证券国际(香港)有限公司 CE AZT137
Cornerstone Investors
#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 3W Funds 23,324,400 HKD 2.07% 6 months 2022-02-20
2 Aspex Master Fund 77,745,150 HKD 6.89% 6 months 2022-02-20
3 Boyu Capital Opportunities Master Fund 77,745,150 HKD 6.89% 6 months 2022-02-20
4 Goldstream Healthcare Focus Fund SP 23,324,400 HKD 2.07% 6 months 2022-02-20
5 Lake Bleu Prime Healthcare Master Fund Limited 77,745,150 HKD 6.89% 6 months 2022-02-20
6 LYFE CAPITAL FUND III (DRAGON), L.P. 38,868,300 HKD 3.44% 6 months 2022-02-20
7 Octagon Investments Master Fund LP 77,745,150 HKD 6.89% 6 months 2022-02-20
8 Sage Partners Master Fund 38,868,300 HKD 3.44% 6 months 2022-02-20
9 Superstring Capital Master Fund LP 38,868,300 HKD 3.44% 6 months 2022-02-20
10 The Valliance Fund 38,868,300 HKD 3.44% 6 months 2022-02-20
Directors & Management
Chairman王國輝
Company Secretary張涵,歐陽偉
No director data available.
Major Shareholders
Major Shareholders & Holdings王國輝(29.2%);LYFE Capital Management Limited(13.64%)
IPO Timeline
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics